Close Menu

NEW YORK — Swedish cancer diagnostics firm Immunovia said on Thursday that it has raised approximately SEK 398 million ($43.0 million) in gross proceeds through the sale of stock to certain institutional investors.

Through the transaction, Immunovia issued 2,948,228 million shares of its stock at a price of SEK 135 apiece to both international and domestic investors. Kempen & Co and Danske Bank acted as joint global coordinators, as well as joint bookrunners along with Vator Securities.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.